Company Overview and News

MPX Responds to Arizona Court of Appeals Decision

2018-07-06 globenewswire
TORONTO, July 06, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) released the following statement in response to the decision by the Arizona Court of Appeals rendered on June 26, 2018 affirming the Yavapai County Superior Court decision convicting Rodney Christopher Jones of possessing a jar containing 0.05 ounces of “hashish.” The Company’s statements come after careful review, consultation with advisors and statements from the regulators.

MPX Completes Acquisition of Canadian Licensed Producer

2018-06-11 globenewswire
TORONTO, June 11, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that it has successfully completed the acquisition of 100% of the issued and outstanding shares (the “Canveda Shares”) of 8423695 Canada Inc. operating as Canveda (“Canveda”), as previously announced on April 17, 2018. Canveda is a Licensed Producer under Health Canada’s Access to Cannabis for Medical Purposes Regulations having received its Cultivation License on June 12, 2017.

MPX Bioceutical Corporation to Host Investor Conference Call on June 12, 2018

2018-06-07 globenewswire
TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (CSE:MPX) (OTC:MPXEF) today announced that it will hold a conference call to update investors on the recently completed US$40 million convertible loan financing as well as providing an operational update to investors. The call will be hosted by W. Scott Boyes, Chairman, President and Chief Executive Officer of MPX, on Tuesday, June 12, at 11:00 a.

MPX Appoints Robert Petch to the Board of Directors

2018-06-06 globenewswire
TORONTO, June 06, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that Robert Petch has joined the board of directors of MPX. Mr. Petch has over 30 years of experience in management, strategic planning and financial analysis. With experience on both the buy-side and sell-side of the investment market, Mr. Petch will be a valuable asset on the execution of MPX’s on-going strategy of growth in the North American cannabis industry.

MPX Raises US$40 Million Secured Convertible Loan to Fund Capacity Development of MPX Assets and Acquisitions

2018-05-29 globenewswire
TORONTO, May 29, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that it has successfully completed a US$40,000,000 secured convertible original issue discount loan (the “Convertible Loan”) financing (the “Offering”) maturing on May 25, 2021 (the “Maturity Date”). While non-interest bearing, the Convertible Loan has been issued at a discount price of US$812.

MPX to Present at the Planet MicroCap Showcase 2018 in Las Vegas, NV, April 24-26, 2018

2018-04-23 accesswire
TORONTO, ON / ACCESSWIRE / April 23, 2018 / MPX Bioceutical Corporation ("MPX" or the "Company") (CSE: MPX; OTCQB: MPXEF) announces that it will be participating in a panel discussion on ''What's Next for Cannabis Investors,'' on Tuesday, April 24, 2018, at 1:10 pm (PST) at the Planet MicroCap Showcase in Las Vegas, NV. The Company will also be presenting a corporate update at 9:00 am (PST) on Wednesday, April 25, 2018, in addition to conducting one-on-one meetings the morning of April 26, 2018.

MPX Adds a Fourth Dispensary in Phoenix and Triples Capacity for MPX Concentrate Production in Arizona

2018-04-09 globenewswire
TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that the official opening of the its newest “Health for Life” medical marijuana dispensary in the Metropolitan Phoenix area, located at the junction of E. Main and Crimson in the suburb of Apache Junction. This brings the number of dispensaries under MPX management in Arizona’s Sun Valley to four.

Mpx Enjoys Record Monthly Revenue of Cdn$5.2 Million in Arizona

2018-04-03 globenewswire
TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) has reported that its managed Arizona assets have recorded their best revenue month in March with sales of cannabis and cannabis concentrates hitting the US$4.0 (CDN$5.2) million mark for the first time.

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

5h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Silicon Investor Message Boards

This table lists all message boards related to TSXV:BCC / The Canadian Bioceutical on message board site Silicon Investor.

Data Broadcasting Corp. (DBCC) BCC: Boise Cascade Corporation
Hispanic Broadcasting ( HSP formerly HBCCA ) Spanish radio (AMEX:RDL) (NASDAQ:DBCC) JV
IBCC Clinichem Development Inc. (BCC.A)
NAVR vs. DBCC (Which is the better play) Data Broadcasting (DBCC) - Pick for 97